{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:39:25Z","timestamp":1762454365402,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.jcmgh.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:30:23Z","timestamp":1700238623000},"page":"311-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fatty Acid Esterification as a NASH Therapeutic Target"],"prefix":"10.1016","volume":"17","author":[{"given":"Ikki","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-0273","authenticated-orcid":false,"given":"Daniel F.","family":"Vatner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2023.10.011_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in\u00a0the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib3","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1038\/s41598-021-84577-z","article-title":"The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017","volume":"11","author":"Zhai","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1073\/pnas.1423952112","article-title":"Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids","volume":"112","author":"Vatner","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cmet.2005.06.006","article-title":"Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice","volume":"2","author":"Neschen","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","article-title":"Convergent somatic mutations in metabolism genes in chronic liver disease","volume":"598","author":"Ng","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Linden","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib10","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1128\/MCB.22.23.8204-8214.2002","article-title":"Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition","volume":"22","author":"Hammond","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2337\/db09-1380","article-title":"Glycerol-3-phosphate acyltransferase 1 deficiency in ob\/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity","volume":"59","author":"Wendel","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/0192623311432298","article-title":"Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer","volume":"40","author":"Ellis","year":"2012","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib17","first-page":"279","article-title":"GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner","volume":"17","author":"Smith","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb06532.x","article-title":"Development of our current understanding of bioactive lysophospholipids","volume":"905","author":"Moolenaar","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1388-1981(02)00153-1","article-title":"Lysophospholipid regulation of mononuclear phagocytes","volume":"1582","author":"Lee","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib15","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.4049\/jimmunol.164.10.4996","article-title":"Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes","volume":"164","author":"Goetzl","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcmgh.2023.10.011_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41419-023-05741-z","article-title":"GPAT3 regulates the synthesis of lipid intermediate LPA and exacerbates Kupffer cell inflammation mediated by the ERK signaling pathway","volume":"14","author":"Fan","year":"2023","journal-title":"Cell Death Dis"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X2300190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X2300190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:34:36Z","timestamp":1762454076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X2300190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2352345X2300190X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2023.10.011","relation":{},"ISSN":["2352-345X"],"issn-type":[{"type":"print","value":"2352-345X"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty Acid Esterification as a NASH Therapeutic Target","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2023.10.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}